Table 2.

A. Guidelines Based Therapy Group*
	Exacerbations		P
	No N=66	Yes N=23
Seasonal Asthma Exacerbation Predictive Index (saEPI)	7.00 [6.00–9.00]	9.00 [8.50–11.0]	<0.001
Variables included in the saEPI
Age (years)	10.0 [8.00–13.0]	8.00 [7.00–9.50]	0.01
Total IgE (kU/l)	242 [107–417]	410 [262–531]	0.01
# of Positive Skin Tests	4.00 [3.00–5.75]	4.00 [3.00–5.50]	0.88
Eosinophil %	4.20 [2.47–6.95]	7.30 [4.95–8.35]	0.01
Prior 90 days Exacerbations:
No	55 (83.3%)	14 (60.9%)	0.05
Yes	11 (16.7%)	9 (39.1%)
FEV1/FVC Ratio	78.3 [73.5–84.5]	75.3 [67.1–85.1]	0.28
Exhaled Nitric Oxide (ppb)	21.7 [11.0–34.5]	34.0 [17.0–48.5]	0.09
Treatment Step	4.00 [2.00–5.00]	5.00 [4.00–5.00]	0.01
Variables not included in the saEPI
Eosinophils (cells/uL)	265 [162–430]	380 [350–600]	0.01

B. Guidelines Based Therapy + Omalizumab Group *
	Exacerbations		P
	No N=223	Yes N=36
Seasonal Asthma Exacerbation Predictive Index (saEPI)	8.00 [6.00–9.50]	9.00 [7.00–10.2]	0.01
Variables included in the saEPI
Age (years)	10.0 [8.00–13.0]	9.50 [7.00–11.0]	0.02
Total IgE (kU/l)	233 [132–446]	282 [151–522]	0.42
# of Positive Skin Tests	4.00 [2.00–6.00]	4.00 [3.00–6.00]	0.47
Eosinophil %	4.40 [2.80–6.90]	5.55 [3.97–7.00]	0.06
Prior 90 days Exacerbations:			0.03
No	195 (87.4%)	26 (72.2%)
Yes	28 (12.6%)	10 (27.8%)
FEV1/FVC Ratio	77.4 [71.2–84.5]	76.8 [69.0–83.2]	0.29
Exhaled Nitric Oxide (ppb)	23.5 [14.0–44.8]	28.7 [16.2–54.5]	0.27
Treatment Step	4.00 [2.00–5.00]	5.00 [3.75–5.00]	0.01
Variables not included in the saEPI
Eosinophils (cells/uL)	290 [180–445]	400 [250–508]	0.02

^*Values are counts (percentages), and medians [IQR]. Calculation of the p-values for the independence test between groups was calculated using the Mann-Whitney U test, and the chi-square test for continuous and categorical variables respectively. All variables were obtained at the time of randomization.